Medication info
Glucita Duo Sustained Release Tablet 50/1000 mg

Glucita Duo Sustained Release Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanall Biopharma Co., Ltd.
Appearance
Bright green, oval-shaped, sustained-release film-coated tablet with a convex surface on both sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202019 · Approved 2022.05.13 · Insurance code 655605470

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine did not dissolve completely and was excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablets once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because of its metformin component (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Hanall Biopharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication assists patients with type 2 diabetes in controlling blood sugar levels through the combination of sitagliptin and metformin. It can be effectively managed with diet and exercise. This treatment helps improve blood sugar control and prevent complications of diabetes. Therefore, it is used for blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine did not dissolve completely and was excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablets once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because of its metformin component (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication is a diabetes treatment containing the components sitagliptin and metformin, and there are several important precautions when taking it. First, allergic reactions may occur while taking this medication; if symptoms such as rash, difficulty breathing, or swelling of the face or neck appear, stop taking it immediately and consult a doctor. Second, there is a risk of pancreatitis, which is inflammation of the pancreas, so if abdominal pain, nausea, or vomiting occurs, seek medical attention immediately. Third, patients with severely reduced kidney function, acute infections, dehydration, or heart problems should not take this medication. Fourth, it is advisable for pregnant women, or women who may become pregnant, and lactating women to avoid using this medication. Fifth, hypoglycemic symptoms may occur, so it is necessary to eat regularly and avoid strenuous exercise or drinking alcohol. Sixth, this medication is not recommended for patients with liver dysfunction, and if there are symptoms of liver dysfunction, it should be discontinued. Seventh, this medication should be temporarily stopped before and after surgery or any examinations requiring contrast agents, and it should be resumed only after confirming that kidney function is normal. Eighth, during treatment with this medication, regular kidney function and blood tests should be conducted, and especially elderly patients need to be more cautious. Ninth, the risk of hypoglycemia may increase when this medication is combined with other hypoglycemic agents or certain medications; therefore, it is essential to consult a doctor when taking medications. Finally, in the case of an overdose, contact a medical institution immediately for appropriate treatment, and this medication can be partially removed through dialysis. If any unusual symptoms occur while taking this medication, inform healthcare personnel immediately and follow their instructions.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 13 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. The safest storage temperature is between 1°C and 30°C. It is advisable to avoid places that are too hot or too cold.

Appearance and packaging

Appearance

Bright green, oval-shaped, sustained-release film-coated tablet with a convex surface on both sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.